Celularity and Verséa Ophthalmics team up to bring innovative ocular treatments to patients

Celularity Inc and Verséa Ophthalmics, LLC have entered an exclusive U.S. commercialization agreement to distribute Celularity’s Biovance and Biovance 3L Ocular products.

These placental-derived allografts provide a biological membrane covering for treating ocular surface disease and ocular surgical applications. Biovance 3L Ocular, an acellular 3-layer amniotic membrane, supports the treatment of advanced ocular surface disease and protects underlying tissue during procedures like corneal epithelial defects, pterygium repair, and fornix reconstruction.

The global persistent corneal epithelial defect management market, valued at $8.5 billion, is expected to reach $44.49 billion by 2033.

Read the full press release here.